Results 111 to 120 of about 126,662 (215)

Navigating Uncertainty in MRI Diagnosis: A Human-AI Collaborative Strategy for Stratifying Clinically Significant Prostate Cancer. [PDF]

J Magn Reson Imaging
Fu X, Bao J, Qiao X, Shen J, Zhang Y, Jin P, Ji Y, Zhang J, Su Y, Ji L, Li Z, Wang X, Shen H, Hu C, Liu J.   +14 more
europepmc   +1 more source

Mepce Restrains Ferroptosis in Prostate Cancer Through 7SK–P‐TEFb Pause Control

Advanced Science, EarlyView.
Genome‐wide CRISPR screening identifies MEPCE as a pause‐control regulator that restrains ferroptosis in prostate cancer. MEPCE loss releases P‐TEFb/CDK9 from 7SK snRNP control, enhances RNAPII Ser2 phosphorylation, and accelerates NRF2‐HMOX1‐driven labile iron accumulation and lipid peroxidation, revealing a transcriptional kinetic gate that lowers ...
Tongtong Zhang, Xiangyang Zhan, Jiexiang Zhang, Mingyue Tan, Chuanmin Chu, Guanqun Ju, Xinyu Zhai, Jianyi Gu, Huirong Zhu, Dongliang Xu   +9 more
wiley   +1 more source

Uncovering the diagnostic potential of seminal fluid beyond fertility: cfDNA methylation analysis for the detection of clinically significant prostate cancer. [PDF]

PLoS One
Geis J, Smith JF, Maddala T, Thoreson G, Michel K, Kaminetsky J, Belkoff L, Huang S, Griscom B, Hart JC, Bench S, Ardalani H, Rivas-Yepes L, Civello D, Clark-Langone KM.   +14 more
europepmc   +1 more source

TRIM28‐Derived Peptide Exerts Anti‐Tumor Roles by Stabilizing Tumor Suppressive BRD7 Protein in Multiple Cancers

Advanced Science, EarlyView.
An α‐helical peptide, TAB12, designed to mimic the TRIM28 binding interface, competitively disrupts the TRIM28‐BRD7 interaction, thereby blocking ubiquitin‐mediated degradation of the tumor suppressor BRD7. This stabilization unleashes potent anti‐tumor effects across multiple tumor types with a favorable safety profile, offering a feasible strategy ...
Qingqing Wei, Changning Xue, Mengna Li, Jianxia Wei, Lemei Zheng, Shipeng Chen, Yijie Wang, Yumei Duan, Yanwei Luo, Wei Xiong, Ming Zhou   +10 more
wiley   +1 more source

PSA density for clinically significant prostate cancer detection: a retrospective cohort study on the influence of age and prostate volume. [PDF]

World J Urol
Engelage L, Behnel N, Lumiani A, Bashkanov O, Stadelmeier LF, Tamalunas A, Buchner A, Sroka R.   +7 more
europepmc   +1 more source

Transcription Factor HOXC11 Drives Colorectal Cancer Progression and Metastasis via CAMK2A‐Dependent CXCL5 Upregulation

Advanced Science, EarlyView.
HOXC11 drives colorectal cancer progression by transcriptionally activating CAMK2A, which triggers NF‐κB–dependent CXCL5 upregulation. CXCL5–CXCR2 signaling further reinforces HOXC11 expression through the ERK1/2–SP1 axis, forming a prometastatic positive feedback loop that is effectively disrupted by combined CAMK2A and CXCR2 inhibition.
Qingyang Sun, Hengjie Xu, Sheng Yang, Jiahui Zhou, Chuanxin Tian, Hongxu Nie, Chi Jin, Tuo Wang, Zhihao Chen, Junwei Tang, Yifei Feng, Xiaowei Wang, Yueming Sun   +12 more
wiley   +1 more source

Prostatic Tuberculosis Mimicking Clinically Significant Prostate Cancer in a Patient Presenting With Low Ejaculate Volume: A Case Report. [PDF]

Cureus
Masued M, Anwar M, Jenkinson M, Hare A.
europepmc   +1 more source

Intranasal Delivery of Gallium–Quercetin Nanoparticles for Multi‐Target Ferroptosis Inhibition in Parkinson's Disease

Advanced Science, EarlyView.
Leveraging the chemical similarity between Ga3+ and Fe3+ as well as the antioxidant properties of quercetin, gallium–quercetin nanoparticles (GQNPs) were prepared to integrate iron homeostasis regulation, oxidative stress suppression, and mitochondrial protection for multi‐target ferroptosis inhibition in Parkinson's Disease.
Keyang Xu, Dandan Kou, Xiao Xiao, Bingbing Bai, Caide Liu, Mengyao Wu, Yadan Shi, Mengdan Xu, Xiaoyi Cao, Haodi Qi, Shuhua Wu, Jianfeng Zeng, Mingyuan Gao   +12 more
wiley   +1 more source

Long-Term Observed Risk of Clinically Significant Prostate Cancer After Negative mpMRI and Systematic Biopsy in Biopsy-Naïve Men: A MULTIPROS Subanalysis. [PDF]

Prostate Cancer
Aloufi WD, Zhang X, Szewczyk-Bieda M, Nabi G, Wei C, Manfredi L.   +5 more
europepmc   +1 more source

PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy

Advanced Science, EarlyView.
A PROTAC‐functionalized protein/DNA‐integrated nanoantigen platform is developed to enhance dendritic cell vaccine potency. By combining a VHL‐recruiting peptide‐modified antigen with a sustained expression plasmid within CaCO3 nanoparticles, this system amplifies cross‐presentation, promotes DC maturation, and elicits robust Th1 and CTL responses ...
Peng Liu, Qiang Chen, Zhe Zhou, Yuekang Xu, Jinyao Li   +4 more
wiley   +1 more source